To evaluate this approach, a phase Ib study enrolled 38 patients with locally advanced or metastatic non-squamous NSCLC harboring EGFR mutations and c-Met overexpression who had progressed after prior osimertinib therapy, and assessed the combination of Teliso-V and osimertinib. This evidence concerns the gene MET and non-small cell lung carcinoma.